Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) Reports Increase in Sellers; Strong Momentum for Short Players

June 19, 2018 - By Jimmy Baldridge

The stock of Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) registered an increase of 4.77% in short interest. ASND’s total short interest was 237,200 shares in June as published by FINRA. Its up 4.77% from 226,400 shares, reported previously. With 72,200 shares average volume, it will take short sellers 3 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S – American Depositary Shares’s float is 1.49%.

The stock increased 0.11% or $0.07 during the last trading session, reaching $66.6. About 84,597 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 178.35% since June 19, 2017 and is uptrending. It has outperformed by 165.78% the S&P500.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.77 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 5 analysts covering Ascendis Pharma (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ascendis Pharma has $7900 highest and $50.0 lowest target. $72.60’s average target is 9.01% above currents $66.6 stock price. Ascendis Pharma had 13 analyst reports since January 3, 2018 according to SRatingsIntel. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Tuesday, May 15 by Wedbush. Wedbush maintained the shares of ASND in report on Wednesday, April 4 with “Buy” rating. The firm earned “Buy” rating on Monday, February 26 by Wedbush. The company was maintained on Wednesday, January 17 by J.P. Morgan. Bank of America maintained it with “Buy” rating and $60 target in Thursday, January 25 report. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Outperform” rating by Credit Suisse on Tuesday, March 20. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Friday, January 5. As per Thursday, May 31, the company rating was maintained by Leerink Swann. Wedbush maintained the stock with “Buy” rating in Monday, March 19 report. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Tuesday, February 6.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Nasdaq.com which released: “Investor Expectations to Drive Momentum within Gladstone Commercial, Old Line Bancshares, Randgold Resources …” on June 06, 2018, also Nasdaq.com with their article: “Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism” published on June 06, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” on June 01, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” published on May 26, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” with publication date: May 21, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: